Oxford, UK: Exosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) and Cowen Healthcare Investments.

Additionally, new investors included Panacea Healthcare Venture, Borealis Ventures, and some private investors. Existing investors, Oxford Sciences Innovation and Oxford University also participated in this financing round. Oxford Sciences Innovation, a £300m fund set up in 2016 with backing from several high-profile city investors, previously led a €11.1m (£10m) seed financing round. 

The company said it will use the proceeds to advance its preclinical-stage exosome therapeutics pipeline towards the clinic. Together with the group of Samir EL Andaloussi from Swedish Karolinska Institute the company has worked out a way to use exosomes for targeted delivery of and small molecule and biologic drug modalities such as mRNA, peptides, monoclonal antibodies etc into cells, into the brain and and other body compartments usually not accessible to drugs. 

Engineering exosomes, the body’s vesicular delivery system, is at the core of the Oxford University spin-out from Matthew Wood's group, which hired ex-Ablynx CSO Dr Antonin de Fougerolles in 2016 to lead its business. Evox is developing a proprietary and partnered (Boehringer Ingelheim) pipeline of exosome-based therapeutics for the treatment of rare diseases with unmet medical need.